



Clinical Pharmacology & Toxicology Pearl of the Week

~ Benzodiazepine Tapering: Concepts & Strategies ~

Case:

- ✓ A 50 yo female is admitted to hospital for pneumonia; on review of her medication list, she is prescribed Lorazepam 1-2mg PO qhs PRN.
- ✓ In review with the patient, she endorses near nightly use of Lorazepam 2mg PO qhs, and in addition uses up to an additional 2 mg daily for anxiety throughout the day.
- ✓ She is interested in tapering off her Lorazepam, as she has tried to “quit it all together” and became quite “sick” after trying to do same.

Background:

- ✓ Benzodiazepines exert their clinical effects through inhibitory neurotransmission via GABA-A receptors; they are commonly prescribed for their sedative-hypnotic, anxiolytic, anticonvulsant, and muscle-relaxant properties
- ✓ At times, patients may be inappropriately prescribed benzodiazepines chronically – this is rarely indicated and may lead to harm, especially in the elderly.
 - Careful review of indications and reasons for use is important in all patients prescribed benzodiazepines.
- ✓ Chronic use (usually weeks) can lead to physical dependence – likely a result of changes to GABA-A receptor response and expression, with a relative increase in excitatory neurotransmission.
 - Withdrawal may present as, but is not limited to:
 - Tremors
 - Anxiety
 - Perceptual disturbances
 - Dysphoria
 - Delirium
 - Insomnia
 - Seizures
 - The timeline of withdrawal symptom onset depends on the half-life and duration since last dose.
- ✓ A safe deprescribing strategy is paramount to avoid benzodiazepine withdrawal and its complications.
 - This is commonly done in the form of an inpatient or outpatient slow taper.
 - No extensive evidence exists which identifies the perfect strategy, and regimens require individualized assessment and monitoring.

Considerations:

- ✓ Inpatient vs. Outpatient Setting
 - Reliability, patient function, and comorbidities all play a role in determining safety when considering an outpatient tapering regimen.
 - Patients in the outpatient setting should have access to frequent reassessments by the tapering physician and should be tapered at a slow rate (See below).
 - Inpatient therapy may be advisable if:
 - Unsuccessful prior attempts.
 - Complicated medical comorbidities (especially a history of seizures).
 - Poor reliability or follow-up.
- ✓ What benzodiazepine(s) is the patient on? Consider a dose equivalent change to a longer acting agent.

DRUG (PO; immediate release)	Typical Adult Dose (mg/day)	Comparative Potency (mg)	Onset PO (hours)	Elimination Half-life (hrs.)
Lorazepam (Ativan)	0.5 – 6	1	0.5 – 1	10 – 14
Oxazepam (Serax)	15 – 120	15 – 30	1 – 2	5 – 15
Alprazolam (Xanax)	0.5 – 6	0.5	1	11 – 20
Clonazepam (Klonopin)	0.5 – 4	0.25 – 0.5	0.5 – 1	18 – 50
Diazepam (Valium)	4 – 40	5	0.25 – 0.5	50 – 100
Chlordiazepoxide (Librium)	5 – 100	10	1	30 – 100

- ✓ *NOT COMPREHENSIVE – Data obtained from Lexicomp and UpToDate database; please refer to a trusted resource for most accurate information, as well as additional benzodiazepines not listed above.
 - Although no benzodiazepine has been proven to be superior in tapering, shorter acting benzodiazepines are associated with:
 - Higher dropout rates from discontinuation studies.
 - Worse rebound symptoms.
 - More severe withdrawal.
 - Agents such as Diazepam (Valium) and Chlordiazepoxide (Librium) are favored agents for tapering given their long elimination half-lives, allowing for a gentler taper and less withdrawal potential.
 - It is safe to switch agents for a taper. To do so, it is recommended to:
 - Ensure the patient is agreeable and understands the purpose of this change.
 - Calculate the total daily dose of each benzodiazepine the patient is on, including PRNs.
 - Using the total daily dose of each and calculate the dose equivalent of a longer acting agent (e.g., Chlordiazepoxide, Diazepam).
 - Chlordiazepoxide daily dose may be divided every 6-12 hours.
 - Diazepam daily dose may be divided every 6-12 hours.

- Ensure the patient demonstrates good symptom control and no toxicity after the change is made – may consider starting with 75% of the calculated equivalent dose and adding as needed.
- ✓ Determine a safe rate of taper
 - General recommendations currently advise a 5-25% dose reduction every 1-2 weeks; however, it is important to note that monitoring for withdrawal symptoms will be paramount in determining if rates need to be slowed.
 - When a dose reduction of 50% is reached, some regimens advocate for a “pause” in tapering for up to 2-4 weeks – however, there is no evidence that this is required or beneficial.
 - Some regimens also recommend slowing the taper once the daily dose is <20% - however, what is more important is frequent monitoring for withdrawal and titrating based off symptoms.
 - Recommendations are similar between both inpatient and outpatient settings.

Augmentative Therapies:

- ✓ Numerous theoretical adjunctive therapies have been proposed; the following are interventions which can be considered.
- ✓ Management of co-existent anxiety and depression (Baandrup 2018 & Darker 2015)
 - May be crucial in managing symptoms previously targeted by the patient’s benzodiazepine use.
 - Consider first-line antidepressant/anxiety therapy in liaison with psychiatry.
- ✓ Management of insomnia
 - Based off results of a small study, Melatonin use may provide a safe way to improve perceived poor sleep quality during benzodiazepine tapers (Garfinkel 1999).
 - Additionally, may consider optimizing the timing of benzodiazepine dose qhs to assist with sleep while tapering.
- ✓ Psychosocial Augmentation: Cognitive Behavioral Therapy (CBT)
 - A meta-analysis looking at success of benzodiazepine discontinuation strategies in 9 different trials found that when CBT was added to a tapering regimen, a higher rate of successful discontinuation was seen at 3 months (Darker 2015)

Case Resolution:

- ✓ You calculate the patient’s daily dose to be an estimated 4mg of Lorazepam / day and decide to convert this to the more long acting Chlordiazepoxide 2mg / day, divided q12h.
- ✓ You safely convert her to Chlordiazepoxide while she is admitted for pneumonia, and determine close follow-up in liaison with her GP, suggesting a dose taper of no more than 25% q1-2 weeks – the patient is also in agreement with this. Her GP helps to facilitate psychiatry involvement and CBT therapy for underlying anxiety disorder.

References / Resources

1. Baandrup L et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users (Review). Cochrane Database Syst Rev. 2018;3:CD011481. doi: 10.1002/14651858.CD011481.pub2.
2. College of Physicians & Surgeons of Alberta (CPSA). Benzodiazepines: Use and taper – Clinical tool kit. June 17, 2020.
3. Darker CD et al. Psychosocial interventions for benzodiazepine harmful use, abuse, or dependence. Cochrane Database Syst Rev. 2015;5:CD009652.
4. Finalyson AJR et al. Experiences with benzodiazepine use, tapering, and discontinuation: An internet survey. Ther Adv Psychopharmacol. 2022;12:20451253221082386.
5. Garfinkel D et al. Facilitation of benzodiazepine discontinuation by melatonin: A new clinical approach. Arch Intern Med. 1999;159(20):2456.
6. Lader M & Kyriacou A. Withdrawing benzodiazepines in patients with anxiety disorders. Curr Psychiatry Rep. 2016;18(1):8.
7. Parr JM et al. Effectiveness of current treatment approaches for benzodiazepine discontinuation: A meta-analysis. Addiction. 2009;104(1):13-24.
8. Sud P & Lee, DC. Chapter 72: Sedative-hypnotics. Goldfrank's Toxicologic Emergencies [11th Edition]. 2019.
9. The US National Centre for PTSD. Effective treatments for PTSD: Helping patients taper from benzodiazepines. January 2015.

The Clinical Pharmacology (CP) physician consultation service is available Mon-Fri, 8am-5pm. The on-call physician is listed in ROCA on the AHS Insite page. CP consultations are also available through Netcare e-referral and Specialist Link. You can also find us in the [Alberta Referral Directory](#) (ARD) by searching “Pharmacology” from the ARD home page. Click [HERE](#) for more details about the service.

The Poison and Drug Information Service (PADIS) is available 24/7 for questions related to poisonings. Please call 1-800-332-1414 (AB and NWT) or 1-866-454-1212 (SK). Information about our outpatient Medical Toxicology Clinic can be found in [Alberta Referral Directory](#) (ARD) by searching “Toxicology” from the ARD home page.

More CPT Pearls of the Week can be found [HERE](#).

Created: September 7, 2023

Reviewed: March 12, 2025